Chandra 1978.

Methods	Single centre study Random allocation (method of randomisation not described) Double‐blind treatment ITT analysis
Participants	Clinical diagnosis of aneurysmal SAH confirmed in CSF and on angiography Male:female: treatment group 11:9; placebo group 10:9 Mean age 51 years (range 20 to 65) Excluded: SAH > 7 days, 'relevant associated illness'
Interventions	Tranexamic acid (6 g per day iv in 6 doses) versus identical‐appearing placebo treatment for a treatment duration of 3 weeks No report on surgical interventions
Outcomes	Outcome: deaths from all causes at 3‐week follow‐up Events: rebleeding: reported, not defined; cerebral ischaemia: not reported; hydrocephalus: not reported
Notes	No report on how many rebleeding were established on CT scan or at necropsy
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	In the text, participants were reported to be randomly allocated, but how this was achieved is not reported
Allocation concealment (selection bias)	Low risk	Identical medication; however, unclear how medication was coded
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Neither the investigators nor the patients knew which subjects received which substance"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described in text
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data
Selective reporting (reporting bias)	Unclear risk	Unclear
Other bias	Unclear risk	More male than female participants included, which could point to some form of bias since people with SAH are more often female